Re EMTN Programme

GlaxoSmithKline PLC
7 December 2001


GlaxoSmithKline plc (Aa2/AA) has mandated Credit Suisse First Boston and
Schroder Salomon Smith Barney to lead manage a long dated Sterling benchmark
issue to be launched next week, subject to market conditions. The notes will
be documented under GlaxoSmithKline's recently signed EMTN Programme which
replaces the previous SmithKline Beecham EMTN Programme.


For further information, please contact:

GlaxoSmithKline
UK Media Enquiries
Martin Sutton              [phone]
Alan Chandler              [phone]
Philip Thomson             [phone]

European Analyst/Investor Enquiries
Duncan Learmouth           [phone]
Anita Kidgell              [phone]


This announcement has been approved solely for the purposes of section 21 of
the Financial Services and Markets Act 2000 by Salomon Brothers International
Limited, trading as Schroder Salomon Smith Barney of Citigroup Centre, 33
Canada Square, Canary Wharf, London E14 5LB. Schroder Salomon Smith Barney is
acting for GlaxoSmithKline plc and no one else in connection with the Sterling
Benchmark Issue and will not be responsible to any other person for providing
the protections afforded to clients of Schroder Salomon Smith Barney or for
providing advice in relation to this transaction.